Last edition
News about "Ecopipam clinical trial"
Teva Reports Ecopipam Data in Pediatric Tourette Syndrome
Teva Pharmaceuticals has reported new ecopipam data showing clinically meaningful tic reduction in about 70 percent of pediatric Tourette Syndrome patients within 8 weeks.
Ecopipam Clinical Trial | 05/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members